VWD

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD

Retrieved on: 
Lunedì, Aprile 29, 2024
FDA, Haemophilia, Patient, Bleeding, News, Hospital, Food, Therapy, Von Willebrand disease, Disease, Caregiver, Thrombosis, Health, Coagulopathy, The O'Reilly Factor, VWD, Inherit, Quality of life, VWF, Pharmaceutical industry

Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate.

Key Points: 
  • Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate.
  • The FDA Orphan Drug Designation program provides orphan status to biologics and drugs for rare diseases.
  • "The FDA orphan exclusivity is exciting news for Octapharma and patients who have endured excessive bleeding episodes," said Octapharma USA President Flemming Nielsen.
  • The Factor My Way patient support program is designed by Octapharma USA for those living with VWD and hemophilia A.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Mercoledì, Aprile 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Mercoledì, Aprile 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Ge

Retrieved on: 
Mercoledì, Gennaio 17, 2024
Factor VIII, Senior, Octapharma, Patient, Research, Nosebleed, SLAM, VWD, Trial of the century, Pharmaceutical industry

The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.

Key Points: 
  • The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
  • The results provide compelling evidence for the use of regular prophylaxis in people with VWD.
  • "The new data from the WIL-31 study provide strong evidence for the use of wilate® prophylaxis in people with all types of VWD.
  • In such instances, indirect treatment comparisons can be used to compare the effects of different treatments.

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Retrieved on: 
Martedì, Gennaio 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, INN, Allergy, ATC, Antibody, Plasma, Blood, DDAVP, International, Bleeding, Von Willebrand factor, Injection, Headache, Disease, Coagulopathy, Language, Hypersensitivity, European Medicines Agency, Von Willebrand disease, Select, Anatomy, IIA, VWD, Medical device

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD

Retrieved on: 
Martedì, Dicembre 5, 2023
Woman, Research, Safety, Food, Ageing, Disease, Hematology, Patient, Prevalence, FDA, ABR, Caregiver, MD, Bleeding, VWF, Bes, Haemophilia, Coagulopathy, Quality of life, Shriners Hospitals for Children, Observational study, Therapy, Health, VWD, Pharmaceutical industry, Nursing, Birth control

PARAMUS, N.J., Dec. 5, 2023 /PRNewswire/ -- Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label now includes routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD), the most prevalent bleeding disorder in the United States. Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.

Key Points: 
  • Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.
  • "The approval of wilate® for VWD prophylaxis is a welcome new treatment option that can be life-saving for many patients.
  • Increased use of VWF prophylaxis in VWD patients may lead to improved patient care and a reduced burden of disease."
  • In tandem with this approval, Octapharma USA extends its commitment to patient care through the Factor My Way patient support program.

Pathway to Cures Announces Inaugural Fund Update

Retrieved on: 
Giovedì, Novembre 2, 2023
General Health, Fund Raising, Health, Foundation, Philanthropy, Knowledge, Von Willebrand disease, Organizational founder, VWD, Hope, Biotechnology, MD, Doctor of Philosophy, MBA, Research, Hemostasis, Tan, Science, Blood, Heavy menstrual bleeding, Woman, Investment, Desmopressin, Litre, Parent, Pharmaceutical industry, Management, Pathway

Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.

Key Points: 
  • Pathway to Cures (P2C) held its inaugural fund meeting on Saturday, October 28th in Chicago, Illinois.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation (NBDF), is a venture philanthropy fund focused on investing in early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “Transcutaneous auricular neurostimulation (tAN) is a non-invasive method demonstrating great promise for treating various diseases.
  • “We have reviewed 114 companies over the past few months, whose promising research will accelerate the treatments and cures for rare diseases in the years to come.

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Lunedì, Ottobre 16, 2023
Research, General Health, Pharmaceutical, Philanthropy, Fund Raising, Foundation, Clinical Trials, Science, Biotechnology, Other Philanthropy, Other Science, Health, VNS, MBA, Doctor of Philosophy, Litre, Indian Council of Medical Research, Bleeding, Anemia, Sickle cell disease, MD, Northwell Health, Injury, Von Willebrand disease, VWD, Electricity, Vagus nerve stimulation, Medical research, Desmopressin, Feinstein Institutes for Medical Research, Coagulopathy, Haemophilia, Scientific Advisory Group, Tan, Hemostasis, Nature Communications, Cyclic permutation, Blood, Vagus nerve, Patient, Pharmaceutical industry, Medical device, The New York Times, Cure, Pathway

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

Retrieved on: 
Giovedì, Luglio 6, 2023
VNS, Male, Von Willebrand disease, Partnership, Depression, Bleeding, Nature, Litre, VWD, Urine, Feinstein Institutes for Medical Research, Tan, Anxiety, Anovulatory cycle, Clinical trial, Nature Communications, Haemophilia, Vagus nerve stimulation, Research, Northwell Health, Desmopressin, Cyclic permutation, Bruise, Blood, Feinstein, Mouse, Hematoma, Medical research, FDA, Mental health, Injury, Medical device, Birth control

Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).

Key Points: 
  • Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).
  • Dr. Navid Khodaparast, Chief Science Officer of Spark and Five Liters stated “Von Willebrand Disease is an inherited bleeding disorder in which blood does not clot properly, leading to bleeding events and joint problems.
  • At Five Liters, our primary clinical initiative is to demonstrate that tAN therapy can safely alleviate menorrhagia in females with VWD.
  • Thanks to this partnership and the Nature article, Five Liters is thrilled to move forward with its mission.

Global Von Willebrand Disease (VWD) Treatment Market Report 2023: Increasing Public Awareness Related to VWD Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Giugno 12, 2023
Biotechnology, Pharmaceutical, Health, Bleeding, VWD, Eagle, DDAVP, Type, Government, Lymphocytosis, Von Willebrand factor, VWF, Von Willebrand disease, Patient, Fibrin, Blood, Growth, Diagnosis, Rare, Research, FDA, Hormone replacement therapy, Pharmaceutical industry, Teva

On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.

Key Points: 
  • On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.
  • The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.
  • The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe.
  • North America was observed as the largest market for von Willebrand disease treatment followed by Europe.